drugset
drugset / Trial / NCT01066598

A Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease (cGVHD)

NCT01066598 ↗

Phase 2 Terminated 1 enrolled University Health Network, Toronto Hoffmann-La Roche · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the efficacy of the combination of rituximab and prednisone as initial therapy for chronic graft-versus-host disease (C-GVHD).

Timeline

Start
2010-05
Primary completion
2011-08
Completion
2011-08

Outcome

Outcome not reported

Stopped (Enrollment): “Poor Accrual”

Drugs

EvaluationDrugModalityDoseRoute
Subject Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Background Prednisone Other / unclassified 1 mg/kg —

Indications

chronic graft versus host disease